Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

• Published in: Haematologica (Roma) Vol. 106; no. 9; pp. 2364 - 2373
• Main Authors: Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.
• Format: Journal Article
• Language: English
• Published: Ferrata Storti Foundation 01.09.2021

B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who...